NASDAQ:ALDR - Alder BioPharmaceuticals, Inc.
$12.68
 $-0.10
-0.78%
4:00PM EDT
2019-04-18
Alder BioPharmaceuticals, Inc., is a clinical-stage biopharmaceutical company that discovers, develops and seeks to commercialize genetically engineered therapeutic antibodies with the potential to meaningfully transform current treatment paradigms. Alder's lead pivotal-stage product candidate, eptinezumab, is being evaluated for migraine prevention. Eptinezumab is a monoclonal antibody that inhibits calcitonin gene-related peptide (CGRP), a protein that is active in mediating the initiation of migraine. Alder is additionally evaluating ALD1910, a preclinical product candidate also in development as a migraine prevention therapy. ALD1910 is a monoclonal antibody that inhibits pituitary adenylate cyclase-activating polypeptide-38 (PACAP-38), another protein that is active in mediating the initiation of migraine. Clazakizumab, Alder's third program, is a monoclonal antibody candidate that inhibits interleukin-6 and is licensed to Vitaeris, Inc. Read more at  reuters.com
sector:  health care
industry:  biotechnology
the data below are updated and published after 9pm EDT each trading day
  ALDR     avg for
industry  
  avg for
sector  
42 stocks weight:  0. 86   203. 85   241. 91  
42 stocks rank:  3. 46 K 1. 44 K 1. 05 K
# analyst opinions:  15. 00   14. 51   13. 97  
mean recommendation:  2. 20   2. 09   2. 01  

quick ratio:  14. 43   5. 27   1. 81  
current ratio:  14. 87   5. 62   2. 25  

target price low:  9. 00   84. 80   115. 21  
target price avg:  21. 40   111. 51   137. 51  
target price high:  36. 00   135. 81   157. 84  
1-yr high:  19. 90   114. 23   138. 78  
last close:  12. 68   87. 66   116. 69  
50-day avg:  13. 42   95. 54   123. 44  
200-day avg:  14. 53   94. 25   121. 11  
1-yr low:  9. 80   72. 78   98. 34  
volume:  1. 06 M 4. 11 M 8. 07 M
50-day avg volume:  974. 07 K 2. 76 M 5. 02 M
200-day avg volume:  918. 95 K 2. 92 M 4. 59 M

1-day return:  -0. 78 % -0. 41 % 0. 07 %
this week return:  -4. 08 % -5. 74 % -4. 11 %
12-wk return:  -2. 69 % 1. 61 % -0. 05 %
52-wk return:  -6. 37 % 3. 12 % 8. 78 %

enterprise value (EV):  747. 07 M 48. 94 B 114. 64 B
market cap:  1. 05 B 43. 07 B 104. 73 B
EBITDA:  -284. 02 M 4. 45 B 8. 01 B
enterprise multiple (EV/EBITDA):  -2. 63   4. 22   12. 73  
total debt:  182. 10 M 12. 24 B 16. 73 B
debt/equity:  85. 20   46. 71   89. 62  
net income (common):  -331. 93 M 2. 20 B 4. 20 B

shares outstanding:  83. 15 M 571. 70 M 1. 24 B
shares:  57. 21 M 571. 81 M 1. 23 B
shares short:  12. 89 M 10. 17 M 13. 00 M
shares short prior month:  13. 74 M 9. 54 M 17. 33 M
short ratio:  11. 83   5. 41   3. 28  
short % of float:  22. 33 % 5. 45 % 2. 38 %
total cash/share:  5. 95   11. 14   9. 33  
total cash:  407. 37 M 6. 71 B 7. 15 B
free cash flow:  -150. 96 M 3. 58 B 2. 96 B
operating cash flow:  -250. 85 M 4. 15 B 4. 30 B

book value:  1. 61   12. 78   26. 92  
price/book:  7. 89   3. 06   -1. 74  
gross profits:  -161. 99 M 8. 04 B 34. 86 B
operating margins:  0. 00 % -725. 35 % -89. 04 %
EBITDA margins:  0. 00 % 10. 94 % 22. 51 %
profit margins:  0. 00 % 7. 81 % 10. 57 %
gross margins:  0. 00 % 37. 08 % 55. 70 %

1-yr max volatility:  17. 47 % --- ---
1-yr mean volatility:  0. 03 % 0. 03 % 0. 04 %

1-yr EPS:  -4. 87   2. 40   4. 10  
forward EPS:  -3. 21   3. 97   7. 13  
P/E:  -2. 60   13. 63   22. 72  
forward P/E:  -3. 95   -15. 95   13. 99  
PE/G:  0. 12   -1. 65   -1. 32  
growth:  -20. 91 % 127. 12 % 29. 61 %
earnings high:  0. 00   1. 00   1. 66  
earnings avg:  -1. 03   0. 77   1. 53  
earnings low:  -1. 42   0. 50   1. 39  
revenue high:  75. 00 M 2. 68 B 10. 78 B
revenue avg:  6. 82 M 2. 59 B 10. 57 B
revenue low:  -0. 00   2. 49 B 10. 36 B
return on assets:  -49. 11 % -2. 75 % 4. 55 %
return on equity:  -120. 25 % -18. 45 % 5. 46 %

beta (1yr vs S&P500):  1. 69   1. 25   0. 93  
sharpe (1yr):  0. 14   0. 37   0. 70  

held % insiders:  5. 20 % 6. 39 % 3. 38 %
held % institutions:  101. 40 % 78. 14 % 68. 52 %

Research more with google or yahoo!
the data below are updated and published after 9pm EDT each trading day

2019-04-21 : ALDR
.        + 0 =             0 :: INITIAL WEIGHT
.   + 43.783 =        43.783 :: inverse volume-to-price addition
.   + 40.632 =        84.415 :: spline projection addition
.    x 3.982 =       336.158 :: 13 weeks' performance factor
.    x 0.934 =       313.919 :: one-year gains+dividend factor
.    x 1.431 =       449.351 :: industry recommendation factor
.    x 1.792 =       805.276 :: symbol recommendation factor
.    x 0.995 =       801.321 :: return on assets factor
.    x 0.988 =       791.685 :: return on equity factor
.    x 2.644 =      2092.864 :: current ratio factor
.    x 1.037 =      2169.399 :: quick ratio factor
.    x 1.041 =       2259.23 :: short ratio factor
.    x 2.162 =      4883.962 :: price-to-book factor
.    x 1.084 =      5296.611 :: debt-to-equity factor
.    x 2.132 =     11293.161 :: P/E weight
.    x 1.684 =     19016.104 :: PE/G factor
.    x 1.358 =     25825.952 :: beta factor
.    x 0.143 =      3682.105 :: sharpe factor
.    x 0.946 =      3483.742 :: target low factor
.    x 1.276 =      4446.735 :: target mean factor
.    x 1.136 =      5049.775 :: target high factor
.     x 1.31 =      6614.639 :: industry 2-weeks return factor
.    x 0.978 =      6468.591 :: "drift" penalty 1 days ago
.    x 0.975 =      6304.399 :: "drift" penalty 3 days ago
.    x 0.911 =      5740.223 :: "drift" penalty 4 days ago
.    x 0.934 =      5363.179 :: overall "drift" factor
.    x 0.825 =      4426.185 :: largest single-day jump factor
.    x 0.222 =       983.597 :: low price factor
.      x 1.0 =       983.437 :: factor hist industry gain for week 16
.   cubeRoot =         9.944 :: reduced to standardize
.    - 21.52 =         0.857 :: add/subtract for performance
.                      0.857 :: FINAL WEIGHT for NASDAQ:ALDR


 


News feed RSS items generated from finance.google.com

News feed formatting by feed2js.org